Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Stroke in Patients with Nephrotic Syndrome: Experience from Two Centers in Poland.
G Ital Nefrol
October 2024
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland.
Article Synopsis
- Patients with nephrotic syndrome (NS) are at higher risk for acute ischemic stroke (aIS) and intracranial hemorrhage (ICH), but the specific risk factors for these outcomes were previously unclear.
- A study analyzed a cohort of NS patients from 2010-2021, identifying significant stroke risk factors including diabetes mellitus, diabetic nephropathy, smoking, prior arterial thromboembolic events, and being over 55 years old.
- Contrary to expectations, the use of low molecular weight heparin did not lower stroke risk, and the findings emphasize the need for careful management of high-risk NS patients.
Exposure to Mycophenolic Acid and Its Clinical Response in an Indian Pediatric Population with Nephrotic Syndrome.
Indian J Nephrol
May 2024
Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.
Background: Children with nephrotic syndrome experience many side effects and frequent relapses when treated with steroids and other drugs. Mycophenolic acid (MPA) is one of the effective and least toxic drug for the treatment of nephrotic syndrome. This drug needs to be monitored for maximal efficacy and minimal toxicity.
View Article and Find Full Text PDFRituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center.
J Bras Nefrol
November 2023
Centro Hospitalar Universitário do Porto, Centro Materno-Infantil do Norte, Serviço de Pediatria, Unidade de Nefrologia Pediátrica, Porto, Portugal.
Article Synopsis
- Rituximab (RTX) is a medicine that can help kids with a tough kidney problem called idiopathic nephrotic syndrome (NS).
- A study looked at 16 kids who received RTX, finding that many improved after treatment, with some showing no symptoms after two years.
- Overall, RTX was found to be effective and safe for treating this condition, helping kids have fewer health issues and take less medication.
Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study.
J Am Soc Nephrol
September 2021
Division of Research, Kaiser Permanente Northern California, Oakland, California.
Background: Little population-based data exist about adults with primary nephrotic syndrome.
Methods: To evaluate kidney, cardiovascular, and mortality outcomes in adults with primary nephrotic syndrome, we identified adults within an integrated health care delivery system (Kaiser Permanente Northern California) with nephrotic-range proteinuria or diagnosed nephrotic syndrome between 1996 and 2012. Nephrologists reviewed medical records for clinical presentation, laboratory findings, and biopsy results to confirm primary nephrotic syndrome and assigned etiology.
Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country.
Pediatr Nephrol
September 2021
Department of Pediatrics, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
Background: Oral cyclophosphamide (CYP) is an important therapeutic agent in treatment of steroid-sensitive nephrotic syndrome having a steroid-dependent (SD) or frequent relapsing (FR) course. This retrospective observational study aimed to determine response to oral CYP and factors associated with positive response in these patients.
Methods: We studied 100 children (male; 75) with FR (19%) and SD (81%) NS treated with CYP in the Pediatric Nephrology clinic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!